Medical Developments International Limited

As of June 30, 2025, Medical Developments International Ltd. carries a market capitalization of 36.31M, placing it among publicly traded companies globally. Its enterprise value stands at 25.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Medical Developments International Ltd.'s next confirmed earnings release is scheduled for February 25, 2027.

As of June 30, 2025, Medical Developments International Ltd. has 112.66M shares outstanding.

As of June 30, 2025, Medical Developments International Ltd. trades at a trailing price-to-earnings ratio of 572.99. The price-to-sales ratio is 1.38, and the price-to-book ratio stands at 1.00.

As of June 30, 2025, Medical Developments International Ltd. trades at an EV/EBITDA multiple of 27.25 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 25.88M versus a market cap of 36.31M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Medical Developments International Ltd. maintains a current ratio of 4.54, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 3.61, indicating elevated leverage, while an interest coverage ratio of 19.24 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2025, Medical Developments International Ltd. posted a return on equity (ROE) of 0.19, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -1.87, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.15, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.26, useful for judging operating efficiency across full business cycles. Inventory turnover of 1.06 indicates how many times Medical Developments International Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2025, Medical Developments International Ltd. recorded 48,703.44 in income tax expense. That works out to an effective tax rate of 44.05, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 110,569.96, leaving 61,866.53 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 13, 2026, Medical Developments International Ltd.'s stock has declined approximately 15.08% over the past 52 weeks.

Over the twelve months ended June 30, 2025, Medical Developments International Ltd. generated 25.70M in revenue and converted that into 61,866.53 in net income, yielding earnings per share of 0.00. EBITDA reached 949,716.99, while operating income came in at -1.16M.

As of June 30, 2025, Medical Developments International Ltd. holds 11.74M in cash and equivalents against 1.31M in total debt, resulting in a net debt position of -11.74M. Total book value stands at 36.27M, with working capital of 18.24M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Medical Developments International Ltd. posted a gross margin of 75.35, reflecting its pricing power and cost economics. The operating margin of -4.51 and net profit margin of 0.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -15.73, meaning Medical Developments International Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Medical Developments International Ltd.'s most recent stock split took place on July 30, 2024.

As of June 30, 2025, Medical Developments International Ltd. has an Altman Z-Score of 2.45, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.